ArticleBlood cancer discovery2021

Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Erin W Meermeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.